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Zusammenfassung
Hintergrund: Die Prognose von Patienten mit malignen
Astrocytomen und Hirnmetastsen ist, trotz intensiver
Therapie, oft fatal. Ziel dieser Studie war es deshalb zu
untersuchen, ob die Lebensqualität (QoL) einen Einfluss
auf das Überleben zeigt. Patienten und Methode: Von
1997 bis 2000 wurden 153 Patienten untersucht. 39 (26%)
lehnten eine Teilnahme an der Studie ab, 47 wurden aus-
geschlossen (14% cerebrales Unvermögen, 3% Sprach-
probleme, 7% Karnofsky Index < 50%, 8% Tod, 7% keine
Compliance). 57 Patienten waren auswertbar (33 mit pri-
mären Hirntumoren, 24 mit Hirnmetastasen). Mit dem
FACT-G Fragebogen wurden krebsspezifische Aspekte
der QoL gemessen. Ergebnisse: Patienten mit Hirnmetas-
tasen zeigten im körperlichen Bereich eine niedrigere
QoL als Patienten mit Astrocytomen; Unterschiede im
Überleben von Patienten konnten zwischen beiden Grup-
pen nicht erkannt werden. Das mediane Überleben von
Patienten mit einer guten QoL betrug 31,3 Monate vs.
14,2 Monate von Patienten mit schlechter QoL. Nur die
zwei Variablen «Leben mit Angehörigen» und der FACT-
G Summenwert zeigten bei der Modellierung mit einer
Cox-PH Regression einen signifikanten Einfluss (p =
0,033 and p = 0,003) auf das Überleben. Patienten, die
nicht mit Angehörigen zusammenlebten, hatten eine kür-
zere Überlebenszeit als die anderen Patienten. Schluss-
folgerung: QoL kann dabei helfen, Patientengruppen mit
einem höheren Sterberisiko zu identifizieren.
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Summary
Background: The prognosis for patients with malignant
astrocytoma or brain metastases is often fatal despite in-
tensive therapy. Therefore we wished to elucidate
whether the quality of life (QoL) is a determinant of over-
all survival (OAS). Patients and Methods: From 1997 to
2000 153 patients with brain tumours were screened; 39
patients (26%) refused to participate and further 47 pati-
ents were excluded (cerebral impairment 14%, amauro-
sis/language problems 3%, Karnofsky performance score
< 50% 7%, death 8%, non-compliance 7%). Thus, 57 pati-
ents were analysed (33 with primary brain tumours, 24
with brain metastases). With the FACT-G questionnaire
cancer-specific aspects of health-related QoL were asses-
sed. Results: Patients with metastases showed a lower
QoL in the physical sphere than patients with astrocyto-
ma, but there were no significant differences in OAS.
Median survival of patients with good QoL was 31.3
months versus 14.2 months in patients with bad QoL.
Only the two variables ’living with a spouse‘ and FACT-G
sum score had a statistically significant influence on sur-
vival (p = 0.033 and p = 0.003) modelled by the Cox-PH
regression. Patients who did not live with a spouse had
shorter survival times than the other patients. Conclusi-
on: Health-related QoL can serve to identify a patient
group with higher risks of death.
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Background
The prognosis for malignant astrocytoma, especially for
glioblastoma multiforme, as well as for brain metastases of dif-
ferent other primaries is fatal in most cases despite intensive
therapy. Current possible therapy options are surgery and ex-
ternal beam radiotherapy. Chemotherapy and more special
techniques such as radiosurgery or implantation of radioac-
tive devices are not yet part of widely used standard treatment
protocols. Therapy is usually designed to prolong patients’
survival and often has no curative intent. Thus, not only the
duration of survival alone but also the quality of life (QoL) of
these patients is an important end-point when it comes to
making decisions about a therapy regimen. Faller et al. [1] and
other investigators have already shown that the psychological
state, i.e. emotional well-being, depressive symptoms and cop-
ing methods of the patient, has an influence on survival [2–4].
There has been little published research, however, on the
health-related QoL of high-grade astrocytomas. Most of the
few existing studies do not use validated or cancer-specific
QoL instruments but rely on performance indices, self-devel-
oped instruments, neuropsychological testing instruments (e.g.
the Mini Mental State Inventory, MMSI), opinion of treating
physicians or interviews instead [5–7]. Other recent work did
use validated testing instruments but merely described the re-
sults without the effort to use them to improve current clinical
practice [8–10]. Our primary hypothesis was that patients with
a below-average QoL could be at risk for an earlier death.
Second, we presumed that in this final stage of disease, med-
ical variables are not as important as usually considered. In
this study, we wish to elucidate whether QoL, assessed with a
validated QoL instrument, is a determinant of survival. 
Patients and Methods
All patients were treated at the Department of Radiotherapy and Radio-
oncology at Klinikum Grosshadern Ludwig Maximilian University, Mu-
nich. The patients were asked to fill in the following 2 questionnaires at
the beginning of their radiotherapy:
The self-developed Current Situation in Personal Life questionnaire (LS)
assessed important sociodemographic variables and parameters in the
personal life of the patients. They were asked to supply information about
marital status, whether or not they were living with a spouse or with fri-
ends, the number of children, and the number of persons in the house-
hold. Furthermore, the instrument assessed the levels of secondary and
professional education, the current type of employment and the current
capacity to work in categories like doing one’s job part-time, full-time or
being temporarily or permanently off work due to medical reasons. 
As far as the disease was concerned, patients were asked about the inci-
dence of cancer in their family history, about the first symptoms of their
disease and whether they had someone to look after them. 
Additional items taken into account were the patients’ relationships with
friends, their hobbies, their religion and spirituality, their social life and
peer groups. Patients were asked to supply information about what they
considered to be significant events in the previous two weeks and in the
preceding year. 
The Functional Assessment of Cancer Therapy – General (FACT-G), ver-
sion 3 questionnaire was developed to assess cancer-specific aspects of
health-related QoL with good overall results for reliability and validity
[11]. The Fact-G count of 5 subscales evaluated physical (0–28 pts), social
and family (0–28 pts), emotional (0–20 pts) and functional well-being
(0–28 pts) and the patients’ relationships with doctors (0–8 pts). These va-
rious QoL domains were assessed as a function of treatment with 29 items
each being scored in 1–5 categories. This resulted in an overall score ran-
ging from 0–112 pts. Although there is a module specific for brain cancer
patients (FACT-BR) which could have been used for patients with pri-
mary brain tumours [12], we omitted this additional module because there
was no information about the use of this instrument for patients with
brain metastases. Medical data were obtained from the hospital files.
Patients were eligible for the study if they suffered from a malignant in-
tracranial neoplasma which required external beam radiotherapy. They
had to be at least 18 years of age and to understand and read German pro-
perly. They had to be physically and mentally able to fill out the que-
stionnaire without any help of others. Mental capacity was assessed by a
modified abbreviated version of the MMSI; physical state was assessed by
the Karnofsky performance index. Patients had to have a Karnofsky per-
formance score (KPS) of 50 or above to be eligible for the study. Patients
suffering from a second disease of any kind with an infaust prognosis were
excluded. Thus, none of the study patients died from any other cause than
the tumour they were suffering from. 
The questionnaires were handed to the patients before their first fraction
was delivered. Patients were explained the aims of the study, were infor-
med about the way the questionnaire data should be evaluated and that
participation in the study and their therapy were not at all linked. They
were then asked to give written informed consent and to fill out the que-
stionnaires in the following 7 days. The second visit was after the last irra-
diation dose had been delivered. Patients were handed out the second set
of questionnaires and were again motivated to continue participating in
the study. The third point of measurement was 6 weeks after completion
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Assessed for 
eligibility 
(n=153) 
Patients 
receiving first 
questionnaire  
(n = 74) 
Excluded (n = 74) 
- cerebral impairment (n = 20) 
- KPS < 50 (n = 10) 
- amaurosis, language problems, 
illiteracy (n = 5) 
- refused to participate (n = 39) 
Analyzed with 
complete data  
(n = 57) 
Lost to follow up (n = 22) 
- died before return of 
questionnaire(s) (n = 12) 
- non-compliance and other (n = 10)
Fig. 1. Patients’ course from screening to evaluation (CONSORT-
criteria).
of the radiation therapy. Since most patients had then left the clinic, the
questionnaires were mailed to the patients with a free return envelope in-
cluded. All 3 questionnaire batteries included a letter which repeated the
main points of the study. It was stated clearly and repeatedly that partici-
pation was completely voluntary and would not at all influence therapy or
follow up. During the period of recruitment (December 1997 – October
2000), 153 patients with cerebral irradiation were screened. 39 patients
(25.5%) refused to participate, a further 47 patients were excluded becau-
se they did not meet the inclusion criteria, 10 patients did not return their
questionnaires. This resulted in 57 eligible patients with complete data
(fig. 1). 33 Patients suffered from primary brain malignoma; 11 had grade
III astrocytoma and 18 glioblastoma multiforme, 4 had primary brain tu-
mours of different histology. 24 patients were irradiated for brain meta-
stases of an extracerebral primary tumour. Table 1 lists the various tu-
mour diagnoses and the sociodemographic data of the patients. Patients
had a median age of 52 years, ranging between 21 and 83 years. Non-par-
ticipants had a median age of 61 years (ranging between 21 and 83 years),
48.5% of them were females. Their median KPS score was 70.
To ensure that our analysis was not influenced by selection bias, the distri-
bution of patients into participants and non-participants was assessed by
means of the chi-square test. None of the medical variables turned out to
differ significantly between the two groups. The only exception was KPS;
significantly more patients with a KPS of 80 and below refused to partici-
pate in our study. On the one hand, this was mostly a result of the inclusi-
on criteria which explicitly excluded patients with a KPS below 50. On the
other hand, this phenomenon was frequently seen in QoL investigations
and thus should not diminish the validity of our results.
The data were analysed with the Kaplan-Meier analysis and the Cox re-
gression analysis using the statistical package SPSS® for Windows version
10.0. 
Results 
Results of the FACT-G QoL measurement were calculated for
the whole group of patients and are shown in table 2. The re-
sults are markedly lower than the ones previously described in
the literature [12]. At the initial point of assessment, we found
a markedly lower QoL in the physical sphere for patients with
brain metastases which resulted in a lower overall QoL for pa-
tients with metastases (22.6 vs. 16.9). There were no differ-
ences in other subscales between these two groups, neither in
any of the other subscales nor at the other points of assess-
ment (table 2). 
Patients with primary brain tumours had a median survival of
26.4 (95% CI = 13.96–38.84) months, which is comparable to
the median survival of 28.3 (95% CI = 0–58.85) months for
patients with brain metastases. There was no statistically sig-
nificant difference between the survival curves (log rank test,
p = 0.86). The other striking fact was that in contrast to clinical
experience and the findings in the literature, the survival times
seemed unexpectedly long. The reason for this is that our
completely unselected patient sample contained 34.4%
anaplastic astrocytomas and 12.5% brain tumours of a differ-
ent histological origin. Figure 2 shows the survival curves for
both groups. 
We were further encouraged by this result to look for another
factor that would show some influence on our patients’ sur-
vival. We suspected that health-related quality of life might be
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Table 1. Sociodemographic and medical data of patients
CNS primary (n = 33) Metastases (n = 24)
Age, years
Median 51 52.5
Range 21–83 29–78
n % n %

18–55 21 63.6 15 62.5
> 55 12 36.4 9 37.5
Sex
Female 10 30.3 12 50.0
Male 23 69.7 12 50.0
Karnofsky Performance Score
< 80 11 33.3 12 50.0
90–100 22 66.7 12 50.0
Primary tumour
Lung cancer 9 37.5
Colon cancer 1 4.2
Gall bladder cancer 1 4.2
Malignant melanoma 1 4.2
Testicular cancer 3 12.5
Laryngeal cancer 1 4.2
Breast cancer 5 20.8
CUP 2 8.3
Soft tissue sarcoma 1 4.2
Surgery
No 6 18.2 10 41.7
Yes 27 81.8 14 58.3
Chemotherapy
No 33 100.0 11 45.8
Yes 13 54.2
Relapse therapy
No 26 78.8 23 95.8
Yes 7 21.2 1 4.2
Marital status
Single 8 24.2 6 25.0
Married 23 69.7 14 58.3
Other 2 6.1 4 16.7
Living with a spouse
No 7 21.2 7 29.2
Yes 26 78.8 17 70.8
Health insurance
State 12 36.4 16 66.7
Private 21 63.6 8 33.3
Level of secondary education
None/low 7 26.9 7 38.9
Medium 6 23.1 7 38.9
High 13 50.0 4 22.2
Professional education
Non-academic 16 59.3 13 59.1
Academic 11 40.7 9 40.9
Hospitalisation 
Outpatient 14 42.4 11 45.8
Inpatient 19 57.6 13 54.2
important for patients with lower QoL who might normally
have shown lower survival rates. 
We wanted to differentiate between good and bad QoL with
acceptable sample sizes in both groups. Therefore the cut-off
point was drawn along the 40th percentile in the FACT-G sum
score values (cut-off point 73), which resulted in 33 (61.1%)
patients with good and 21 (38.9%) patients with bad QoL. The
background of this choice of cut-off point was a capacity
analysis in our department considering the number of physi-
cians with a supplementary training in psychooncology. The
result of this analysis was that about 40% of patients could be
subject to an additional psychological intervention. Since our
situation in Munich is likely to be similar to other radiooncol-
ogy departments, we chose this cut-off point to define patients
with ‘bad QoL’. The median survival of patients with good
QoL was 31.3 months vs. only 14.2 months in patients with
bad QoL estimated by Kaplan-Meier; log-rank testing re-
vealed a significant result (p = 0.0039) (fig. 3). 
The next step was to find out whether there were certain fac-
tors that could predict survival in our patient sample. There-
fore Cox-PH regression was performed with the following po-
tential risk factors: primary tumour (brain/other), surgery
(yes/no), medical insurance mode (state/private), comorbidity
(number of concomitant diseases), the level of secondary edu-
cation (none or low/medium/high), level of professional edu-
cation (academic/non-academic), patient type (inpatient/out-
patient), relapse therapy (yes/no), age, KPS, total dose in main
radiation field, living with one’s spouse (yes/no), sex (male/fe-
male), FACT-G sum score. 
Only two variables ‘living with one’s spouse’ (yes/no) and
FACT-G sum score (p = 0.033 and p = 0.003) had significant
influence on survival (table 3). Living with a spouse and a
higher FACT-G sum score was associated with a longer ex-
pected survival. It was remarkable that somatic variables did
not influence survival.
Discussion
Of the patients who were approached, 25.5% refused to par-
ticipate. However, we had a heterogeneous sample of patients
as well as a relatively positive selection of patients as a result
of the strict criteria for inclusion. It is not possible to deter-
mine how psychologically representative the participants were
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Table 2. Distribution of HRQoL-measurement with FACT-G; in patients with primary brain tumours and brain metastases
CNS primary (n = 33) CNS metastases (n = 24) Whole sample F value p-Value
    
mean SD mean SD mean SD
Physical well-being before therapy 22.56 5.10 16.93 7.26 20.24 6.63 11.629 0.0012
end of therapy 18.06 7.09 16.79 6.81 17.57 6.92 0.325 0.5717
6 weeks after therapy 21.09 6.90 17.27 6.56 19.77 6.92 2.284 0.1412
Family, friends before therapy 21.99 5.01 20.70 3.25 21.44 4.36 1.217 0.2747
end of therapy 20.10 5.65 19.61 3.79 19.91 4.97 0.091 0.7649
6 weeks after therapy 21.63 3.65 20.44 4.04 21.21 3.76 0.713 0.4053
Relationship to doctor before therapy 6.52 1.57 6.71 1.43 6.60 1.49 0.219 0.6414
end of therapy 6.31 1.62 6.53 1.30 6.39 1.49 0.212 0.6481
6 weeks after therapy 6.19 1.86 6.56 1.42 6.30 1.72 0.275 0.6041
Emotional well-being before therapy 14.17 4.55 12.33 3.36 13.38 4.15 2.786 0.1009
end of therapy 14.18 4.74 13.53 3.54 13.94 4.30 0.212 0.6477
6 weeks after therapy 13.78 4.55 14.34 3.35 13.97 4.12 0.131 0.7202
Functional well-being before therapy 17.06 6.41 14.24 5.32 15.85 6.08 3.056 0.0861
end of therapy 16.55 6.77 15.27 4.68 16.08 6.06 0.421 0.5202
6 weeks after therapy 17.33 6.51 14.62 4.45 16.40 5.95 1.528 0.2261
Sum score before therapy 82.37 15.81 71.19 14.30 77.60 16.04 7.154 0.0100
end of therapy 75.20 17.11 71.97 15.96 74.01 16.56 0.355 0.5545
6 weeks after therapy 80.02 18.75 72.64 13.33 77.80 17.41 1.138 0.2951
Table 3. Prognostic factors for survival by Cox-PH analysis
Prognostic factor Maximum Standard error Chi-square  p-Value Risk ratio 95% Confidence 
Likelihood test statistic interval for risk ratio
FACT-G sum score -0.048 0.016 12.460 0.003 0.953 0.923–0.984
Spouse 1.691 0.793 11.158 0.033 5.426 1.146–25.659
of all the patients with brain tumours seen in our department.
The results of the treatment of patients in one radiotherapy
department could possibly be applicable to other hospitals as
well. It is reasonable to assume that those who refused to par-
ticipate were no less psychologically reactive than other pa-
tients and that our patient sample was representative of a uni-
versity radiotherapy department. 
We found markedly lower QoL values than previously de-
scribed in the literature. This might be due to two factors:
First, since we only included patients with high-grade gliomas
and brain metastases, we chose to work with patients who had
a very limited life expectancy. This restricted view of patients
who had already arrived at the final stage of their disease
seems unique. Thus it is even more important for such patients
that measures are taken to improve their QoL as far as possi-
ble. Secondly, the fact that we did not work with patients who
had primary brain tumours only but also included patients
with brain metastases might have contributed to the worse
overall QoL. Hence, we investigated whether the FACT-G
values for patients with primary brain tumours differed from
those for patients with brain metastases. 
The difference was significant only at the initial measurement
and only in the subscale for physical well-being, and accord-
ingly for the sum score, because this subscale contributes sig-
nificantly to the whole FACT-G value. At the two latter mea-
surements, no significant differences neither in any of the sub-
scales nor in the sum score could be found (table 2). 
From this point of view it seemed possible that patients with
primary brain tumours might have a different expected sur-
vival than those with brain metastases. However, Log-Rank
testing showed no significant difference in survival times. 
In contrast, our primary hypothesis that health-related QoL
(HRQoL) might influence survival was supported by log-rank
testing. This is probably due to our patient selection: Although
our patient group was very heterogenous as to type of disease,
what these patients all had in common was that they were all
to die of their disease and so their treatment was only pallia-
tive. There were already indications that psychological and so-
ciodemographic variables can influence survival in cancer pa-
tients and so we considered a non-selected collective of pa-
tients suitable for such an investigation [1, 13–16]. 
One might argue that HRQoL is just a surrogate parameter
for the medical state of the individual patient. Several recent
studies which focused on various malignant and non-malig-
nant chronic diseases have shown that subjectively perceived
quality of life does not directly correlate with the stage and
the course of disease [17–21].
Apart from merely illustrating that QoL as a variable inde-
pendent of the medical condition of the patient, is linked to
prolonged survival, we also considered it probable that
HRQoL might be among the variables that could predict sur-
vival in our patient group. With the appropriate Cox regres-
sion model shown in table 3 we were finally able to extract
two main informations: Firstly, the model proves the influence
of QoL measured with the FACT-G core instrument. This
clearly supports our above-mentioned hypothesis. Since the
measurement of HRQoL with the FACT-G instrument is well-
established and widely used, there are no serious doubts about
this result. 
However, our results contrast with the findings of Meyers et
al. [22], who state that the results of neuropsychological test-
ing and not QoL scores (assessed with FACT-BR) predict sur-
vival. At first sight, these two results are contradictory. How-
ever, one must take into account the differences in patient se-
lection: Meyers et al. [22] focused on patients with recurrent
disease, excluding patients with metastases. They explicitly in-
cluded patients with severe cerebral deficits which were ex-
cluded by the study protocol in our work. This resulted in a
quota of 15% of their patients not completing the applied
quality of life instrument. Considering these findings and es-
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Fig. 3. Survival of patients with good QoL (FACT-G sum score ≥70 vs.
bad QoL (FACT-G sum score < 70); (p = 0.0039).
pecially the absence of severe neuropsychological and cere-
bral deficits in our patient sample, these differences might well
be attributed to patient selection.
When performing a correlation analysis between the FACT-G
scales and KPS, significant correlations can indeed be mea-
sured. Such is the case only at the initial point of measure-
ment at the scales for physical well-being (correlation coeffi-
cient (CC) 0.344, p = 0.01), emotional well-being (CC 0.302, p
= 0.024), functional well-being (CC 0.419, p = 0.001) and for
the sum score (CC 0.381, p = 0.004). Although significant,
these correlations are very moderate; none of them even
reaches beyond the level of 0.5. Thus, this fact does not leave
much space for interpretation as correlations are too weak to
build a lucid argumentation on it. In spite of these moderate
correlations, we omitted KPS in our model to increase its in-
terpretability. 
An additional point that has to be clarified is the use of the
factor ‘living with one’s spouse’ instead of the marital status:
In the past, being married implicitly meant that one was living
together with the partner, and being single meant one was liv-
ing alone. Today, this has changed in western societies: In per-
sons below 40 years, more and more people live together with
their spouse without being married. Thus we decided that this
direct approach might be more appropriate to gather infor-
mation about the situation in reality than the abstract marital
status. 
Health-related QoL is becoming more and more important,
especially for patients facing death from their disease. It can
serve not only to distinguish patients with a longer expected
survival rate from those who might be facing a sooner death
but also to estimate the patient’s survival time. 
Subjective measurements of how patients facing a fatal out-
come from brain neoplasm feel, how they deal with life and
the disease and their psychosocial state as a whole, obviously
carry a greater potential for prolonged life than standard so-
matic factors [23]. It is essential that our findings are applied
to a larger sample of patients to go beyond the natural limita-
tions of a pilot study and that other investigators also eluci-
date the question whether successful attempts to improve
quality of life can promote prolonged survival.
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